GlassScriptPhysician profile
Mandana Mahmoudi
NPI 1942527148
$2,231.62
in general payments reported to CMS, 2019-2025
12 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $434 · 2023: $376 · 2024: $619 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.35 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $855.49 | 2021-2025 | Xywav |
| Harmony Biosciences LLC | $466.19 | 2021-2025 | |
| Inspire Medical Systems, INC. | $216.00 | 2022 | |
| Axsome Therapeutics, INC. | $211.83 | 2024-2025 | Sunosi |
| Zoll Respicardia, INC. | $147.54 | 2024 | Remede System |
| Lilly USA, LLC | $111.79 | 2025 | Zepbound |
| Itamar Medical INC | $62.72 | 2022-2024 | Watchpatone |
| Avadel Cns Pharmaceuticals, LLC | $53.85 | 2024-2025 | Lumryz |
| Ucb, INC. | $39.15 | 2024 | Briviact |
| Advanced Respiratory, INC | $27.42 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.06 | 2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $16.58 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandana Mahmoudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.